Research progress on target therapeutic agents of HER-2 extracellular ligand-binding domain in breast cancer
10.3969/j.issn.1000-8179.20130329
- VernacularTitle:乳腺癌HER-2胞外配体结合区靶点治疗的研究进展*
- Author:
Jinxiu ZHONG
;
Yamei LI
;
Yanxing GUAN
- Publication Type:Journal Article
- Keywords:
HER-2;
breast cancer;
extracellular-targeted agents;
monoclonal antibody;
antibody conjugate
- From:
Chinese Journal of Clinical Oncology
2013;(17):1076-1079
- CountryChina
- Language:Chinese
-
Abstract:
The target therapeutic agents of HER-2 extracellular ligand-binding domain have become the core of breast cancer research. A small peptide molecule and an anti-HER2 extracellular domain monoclonal antibody conjugated with protein toxins, radioisotopes, and chemotherapeutic drugs (immunoconjugate) can improve efficacy and reduce systemic toxicity. Vaccines based on HER-2 extracellular region should protect patients from HER-2-overexpressing breast cancer growth. In this review, studies on targeted-block therapies of the HER-2 extracellular ligand-binding domain in breast cancer were discussed to provide references for clinical applications.
